menu
    • menu

    Company profile for Zhejiang Hisoar Pharmaceutical

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulatio...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Zhejiang Hisoar PharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    No. 100, Waisha Branch Road, Jiaojiang District, Taizhou City, Zhejiang Provin...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hisoar.com/about-en.html
    Linkedin
    Linkedin
    https://www.linkedin.com/company/zhejiang-hisoar-pharmaceutical-co-ltd-/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 955

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2173

    https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

    #PharmaFlow by PHARMACOMPASS
    24 Apr 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Chen Zhicheng, member of the party group and deputy director of the Zhejiang
    Chen Zhicheng, member of the party group and deputy director of the Zhejiang

    05 May 2023

    // PRESS RELEASE

    https://www.hisoar.com/news-detail-en.html?id=302

    PRESS RELEASE
    05 May 2023
    Share Share
    A new batch of
    A new batch of "little giant" enterprises in Jiaojiang District was released

    30 Mar 2023

    // PRESS RELEASE

    https://www.hisoar.com/news-detail-en.html?id=295

    PRESS RELEASE
    30 Mar 2023
    Share Share
    Yan Qijun, deputy mayor of Linhai City, and his party visited Haixiang
    Yan Qijun, deputy mayor of Linhai City, and his party visited Haixiang

    23 Mar 2023

    // PRESS RELEASE

    https://www.hisoar.com/news-detail-en.html?id=293

    PRESS RELEASE
    23 Mar 2023
    Share Share
    Zhejiang Science and Technology Award Publicity Information Form
    Zhejiang Science and Technology Award Publicity Information Form

    20 Feb 2022

    // PRESS RELEASE

    https://www.hisoar.com/news-detail-en.html?id=234

    PRESS RELEASE
    20 Feb 2022
    Share Share
    Zhou Hui, President of China Chamber of Commerce for Import and Export
    Zhou Hui, President of China Chamber of Commerce for Import and Export

    24 Jun 2021

    // PRESS RELEASE

    https://www.hisoar.com/news-detail-en.html?id=194

    PRESS RELEASE
    24 Jun 2021
    Share Share
    Zhejiang Hisoar Pharmaceutical issues 500 mln yuan financing bills
    Zhejiang Hisoar Pharmaceutical issues 500 mln yuan financing bills

    22 Nov 2016

    // REUTERS

    http://www.reuters.com/article/idUSL4N1DO1B8

    REUTERS
    22 Nov 2016
    Share Share

    USDMF

    read-more
    read-more

    01

    Clindamycin Hydrochloride (process B...

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    02

    Clindamycin Palmitate Hydrochloride ...

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    03

    Clindamycin Phosphate (process B)

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    04

    Metoprolol Succinate

    China
    AACR Annual meeting
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CEP/COS

    read-more
    read-more

    01

    Amorolfine hydrochloride

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    02

    Clindamycin hydrochloride, BTC Process

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    03

    Clindamycin phosphate, BTC process

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    04

    Flunixin meglumine for veterinary use, P...

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    05

    Metoprolol succinate

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    06

    Quetiapine Fumarate

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    07

    Repaglinide

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    JDMF

    read-more
    read-more

    01

    Amorolfine Hydrochloride

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Amorolfine Hydrochloride

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Zhejiang Hisoar Pharmaceutical

    Registration Number : 303MF10111

    Registrant's Address : No. 100 Waisha Branch Rd. , Jiaojiang, Taizhou, Zhejiang, China

    Initial Date of Registration : 2021-07-16

    Latest Date of Registration : 2021-07-16

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Clindamycin hydrochlide monohydrate

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Clindamycin hydrochlide monohydrate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Zhejiang Hisoar Pharmaceutical

    Registration Number : 303MF10077

    Registrant's Address : No. 23,5th Donghai Avenue Zhejiang Chemical materials base Linhai zone, Linhai City, ...

    Initial Date of Registration : 2021-05-13

    Latest Date of Registration : 2021-05-13

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Clindamycin phosphate

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Clindamycin phosphate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Zhejiang Hisoar Pharmaceutical

    Registration Number : 226MF10130

    Registrant's Address : No. 23,5th Donghai Avenue Zhejiang Chemical materials base Linhai zone, Linhai City, ...

    Initial Date of Registration : 2014-06-26

    Latest Date of Registration : 2017-08-04

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Clindamycin Phosphate

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Clindamycin Phosphate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Zhejiang Hisoar Pharmaceutical

    Registration Number : 303MF10045

    Registrant's Address : No. 23,5th Donghai Avenue Zhejiang Chemical materials base Linhai zone, Linhai City, ...

    Initial Date of Registration : 2021-03-15

    Latest Date of Registration : 2021-03-15

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Day stations meropenem hydrate (producti...

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Day stations meropenem hydrate (producti...

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Zhejiang Hisoar Pharmaceutical

    Registration Number : 228MF10190

    Registrant's Address : No. 23, 5th Donghai Avenue Zhejiang Chemical materials base Linhai zone, Linhai City,...

    Initial Date of Registration : 2016-10-05

    Latest Date of Registration : 2020-07-01

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Quetiapine fumarate

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Quetiapine fumarate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Zhejiang Hisoar Pharmaceutical

    Registration Number : 229MF10146

    Registrant's Address : No. 23,5th Donghai Avenue Zhejiang Chemical materials base Linhai zone, Linhai City, ...

    Initial Date of Registration : 2017-07-31

    Latest Date of Registration : 2017-07-31

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Repaglinide

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Repaglinide

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Zhejiang Hisoar Pharmaceutical

    Registration Number : 306MF10117

    Registrant's Address : No. 23,5th Donghai Avenue Zhejiang Chemical materials base Linhai zone, Linhai City, ...

    Initial Date of Registration : 2024-08-28

    Latest Date of Registration : 2024-08-28

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Voglibose

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Voglibose

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Zhejiang Hisoar Pharmaceutical

    Registration Number : 302MF10094

    Registrant's Address : No. 100 Waisha Branch Rd. , Jiaojiang, Taizhou, Zhejiang, China

    Initial Date of Registration : 2020-08-05

    Latest Date of Registration : 2021-04-27

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Voglibose "KOA"

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Voglibose "KOA"

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Zhejiang Hisoar Pharmaceutical

    Registration Number : 217MF11015

    Registrant's Address : No. 100 Waisha Branch Rd. , Jiaojiang, Taizhou, Zhejiang, China

    Initial Date of Registration : 2005-11-21

    Latest Date of Registration : 2011-06-15

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KDMF

    read-more
    read-more

    01

    Amorolfine hydrochloride

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Amorolfine hydrochloride

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Registrant Name : Ace Biopharm Co., Ltd.

    Registration Date : 2019-12-04

    Registration Number : 20191204-211-J-495

    Manufacturer Name : Zhejiang Hisoar Pharmaceutical...

    Manufacturer Address : No. 100 Waisha Branch Road. Jiaojiang, Taizhou, China

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    02

    Biphenyl dimethyl dicarboxylate

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Biphenyl dimethyl dicarboxylate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Registrant Name : Hwail Pharmaceutical Co., Ltd.

    Registration Date : 2019-01-31

    Registration Number : 20190131-17-C-373-12

    Manufacturer Name : Zhejiang Hisoar Chuannan Pharm...

    Manufacturer Address : No 23. Donghai 5th Avenue, Zhejiang Chemical Materials Base Linhai Zone, Linhai City,...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    03

    Biphenyl dimethyl dicarboxylate

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Biphenyl dimethyl dicarboxylate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Registrant Name : Ace Biopharm Co., Ltd.

    Registration Date : 2022-09-15

    Registration Number : 20190131-17-C-373-12(1)

    Manufacturer Name : Zhejiang Hisoar Chuannan Pharm...

    Manufacturer Address : No 23. Donghai 5th Avenue, Zhejiang Chemical Materials Base Linhai Zone, Linhai City,...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    04

    Biphenyl dimethyl dicarboxylate

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Biphenyl dimethyl dicarboxylate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Registrant Name : Hwail Pharmaceutical Co., Ltd.

    Registration Date : 2005-08-31

    Registration Number : 20050831-17-C-14-04

    Manufacturer Name : Zhejiang Hisoar Pharm Co., Ltd...

    Manufacturer Address : NO.100, Waisha Branch Rd. Jiaojiang Taizhou Zhejiang, China

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    05

    Clindamycin hydrochloride

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Clindamycin hydrochloride

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Registrant Name : Ace Biopharm Co., Ltd.

    Registration Date : 2021-04-16

    Registration Number : 20210416-210-J-619

    Manufacturer Name : Zhejiang Hisoar Chuannan Pharm...

    Manufacturer Address : No. 23 Donghai 5th Avenue, Zhejiang Chemical Materials Base Linhai Zone, Linhai City,...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    06

    Diquafosol Sodium

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Diquafosol Sodium

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Registrant Name : Ace Biopharm Co., Ltd.

    Registration Date : 2025-01-06

    Registration Number : 289-23-ND

    Manufacturer Name : Zhejiang Hisoar Pharmaceutical...

    Manufacturer Address : No. 100 Waisha Branch Road. Jiaojiang, Taizhou, 318000. Zhejiang China

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    07

    Phosphate clindamycin

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Phosphate clindamycin

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Registrant Name : Ace Biopharm Co., Ltd.

    Registration Date : 2021-02-09

    Registration Number : 20210209-210-J-618

    Manufacturer Name : Zhejiang Hisoar Chuannan Pharm...

    Manufacturer Address : No. 23 Donghai 5th Avenue, Zhejiang Chemical Materials Base Linhai Zone, Linhai City,...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    NDC API

    read-more
    read-more

    01

    CLINDAMYCIN HYDROCHLORIDE

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    CLINDAMYCIN HYDROCHLORIDE

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    NDC Package Code : 67321-301

    Start Marketing Date : 2015-02-22

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    CLINDAMYCIN PALMITATE HYDROCHLORIDE

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    CLINDAMYCIN PALMITATE HYDROCHLORIDE

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    NDC Package Code : 67321-304

    Start Marketing Date : 2020-11-20

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    CLINDAMYCIN PALMITATE HYDROCHLORIDE

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    CLINDAMYCIN PALMITATE HYDROCHLORIDE

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    NDC Package Code : 67321-303

    Start Marketing Date : 2015-02-22

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    CLINDAMYCIN PHOSPHATE

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    CLINDAMYCIN PHOSPHATE

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    NDC Package Code : 67321-302

    Start Marketing Date : 2015-02-22

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    FLORFENICOL

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    FLORFENICOL

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    NDC Package Code : 67321-568

    Start Marketing Date : 2015-02-22

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    FLUNIXIN MEGLUMINE

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    FLUNIXIN MEGLUMINE

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    NDC Package Code : 67321-001

    Start Marketing Date : 2017-10-19

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    METOPROLOL SUCCINATE

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    METOPROLOL SUCCINATE

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    NDC Package Code : 67321-509

    Start Marketing Date : 2015-02-22

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    PHENYLEPHRINE HYDROCHLORIDE

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    PHENYLEPHRINE HYDROCHLORIDE

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    NDC Package Code : 67321-100

    Start Marketing Date : 2015-01-27

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view

    LISTED APIs

    read-more
    read-more
    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Amorolfine Hydrochloride

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    01

    Amorolfine Hydrochloride

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Amorolfine Hydrochloride

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Atorvastatin

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    02

    Atorvastatin

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Atorvastatin

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Biapenem

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    03

    Biapenem

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Biapenem

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bifendate

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    04

    Bifendate

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Bifendate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Caspofungin

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    05

    Caspofungin

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Caspofungin

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Clindamycin Hydrochloride

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    06

    Clindamycin Hydrochloride

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Clindamycin Hydrochloride

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Clindamycin Palmitate

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    07

    Clindamycin Palmitate

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Clindamycin Palmitate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Clindamycin Phosphate

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    08

    Clindamycin Phosphate

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Clindamycin Phosphate

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Crisaborole

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    09

    Crisaborole

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Crisaborole

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Ertapenem Sodium

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are a...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    10

    Ertapenem Sodium

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Ertapenem Sodium

    China
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dye...

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ALL Intermediates

    read-more
    read-more
    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    4-Nitrobenzyl hydrogen malonate

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    77359-11-6
    Meropenem
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed compan...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    01

    4-Nitrobenzyl hydrogen malonate

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    4-Nitrobenzyl hydrogen malonate

    China
    AACR Annual meeting
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    4-Nitrobenzyl hydrogen malonate

    CAS Number : 77359-11-6

    End Use API : Meropenem

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKon...

    blank

    Intermediate Web Link

    Market Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tert Butyl Dimethyl Silyl Chloride

    Intermediate Web Link

    Market Place

    18162-48-6
    Meropenem
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed compan...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    02

    Tert Butyl Dimethyl Silyl Chloride

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Tert Butyl Dimethyl Silyl Chloride

    China
    AACR Annual meeting
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Tert Butyl Dimethyl Silyl Chloride

    CAS Number : 18162-48-6

    End Use API : Meropenem

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKon...

    blank

    Intermediate Web Link

    Market Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    4-(4-Aminophenyl)morpholin-3-one

    Intermediate Web Link

    Market Place

    438056-69-0
    Rivaroxaban
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed compan...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    03

    4-(4-Aminophenyl)morpholin-3-one

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    4-(4-Aminophenyl)morpholin-3-one

    China
    AACR Annual meeting
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    4-(4-Aminophenyl)morpholin-3-one

    CAS Number : 438056-69-0

    End Use API : Rivaroxaban

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKon...

    blank

    Intermediate Web Link

    Market Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    (S)-N-Glycidylphthalimide

    Intermediate Web Link

    Market Place

    161596-47-0
    Rivaroxaban
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed compan...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    04

    (S)-N-Glycidylphthalimide

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    (S)-N-Glycidylphthalimide

    China
    AACR Annual meeting
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    (S)-N-Glycidylphthalimide

    CAS Number : 161596-47-0

    End Use API : Rivaroxaban

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKon...

    blank

    Intermediate Web Link

    Market Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    N-Carbobenzyloxy-L-Valine

    Intermediate Web Link

    Market Place

    1149-26-4
    Amino Acids Mixture
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed compan...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    05

    N-Carbobenzyloxy-L-Valine

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    N-Carbobenzyloxy-L-Valine

    China
    AACR Annual meeting
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    N-Carbobenzyloxy-L-Valine

    CAS Number : 1149-26-4

    End Use API : Amino Acids Mixture

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKon...

    blank

    Intermediate Web Link

    Market Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tert-butyl 2-((4R,6R)-6-(cyanomethyl)-2,2- dimethyl-1,3-dioxan...

    Intermediate Web Link

    Market Place

    125971-94-0
    Atorvastatin
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed compan...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    06

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2-(2-(4-fluorophenyl)-6-(2-aminoethyl)-2,2- dimethyl-1,3-dioxa...

    Intermediate Web Link

    Market Place

    125971-96-2
    Atorvastatin
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed compan...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    07

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2,4-Dimethylbenzenethiol

    Intermediate Web Link

    Market Place

    13616-82-5
    Vortioxetine Hydrobromide
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed compan...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    08

    2,4-Dimethylbenzenethiol

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    2,4-Dimethylbenzenethiol

    China
    AACR Annual meeting
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    2,4-Dimethylbenzenethiol

    CAS Number : 13616-82-5

    End Use API : Vortioxetine Hydrobromide

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKon...

    blank

    Intermediate Web Link

    Market Place

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pneumocandin B?

    Intermediate Web Link

    Market Place

    135575-42-7
    Caspofungin
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed compan...
    Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide.
    blank

    09

    Pneumocandin B?

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    Pneumocandin B?

    China
    AACR Annual meeting
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zhejiang Hisoar Pharmaceutical

    Pneumocandin B?

    CAS Number : 135575-42-7

    End Use API : Caspofungin

    About the Company : Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKon...

    blank

    Intermediate Web Link

    Market Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    EDQM

    read-more
    read-more

    01

    GMP Certified

    EU
    AACR Annual meeting
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    AACR Annual meeting
    Not Confirmed

    Zhejiang Hisoar Pharmaceutical

    Type : GMP Certificates

    Number : DE_HH_01_GM...

    EudraGMDP Key : 52518

    Country : China

    Issue Date : 2019-02-20

    Post Code :

    NCA Ref : 00027475

    City : Zhejiang Province

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    GMP Certified

    EU
    AACR Annual meeting
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    AACR Annual meeting
    Not Confirmed

    Zhejiang Hisoar Pharmaceutical

    Type : GMP Certificates

    Number : DE_NW_01_GM...

    EudraGMDP Key : 49907

    Country : China

    Issue Date : 2018-08-31

    Post Code :

    NCA Ref : 00012170

    City : Jiaojiang Taizhou Zheji...

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    GMP Certified

    EU
    AACR Annual meeting
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    AACR Annual meeting
    Not Confirmed

    Zhejiang Hisoar Pharmaceutical

    Type : GMP Certificates

    Number : DE_BW_01_GM...

    EudraGMDP Key : 33712

    Country : China

    Issue Date : 2016-01-26

    Post Code :

    NCA Ref : 00012170

    City : Jiaojiang Taizhou Zheji...

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    GMP Certified

    EU
    AACR Annual meeting
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    AACR Annual meeting
    Not Confirmed

    Zhejiang Hisoar Pharmaceutical

    Type : GMP Certificates

    Number : IT/E/GMP/AP...

    EudraGMDP Key : 32262

    Country : China

    Issue Date : 2015-11-19

    Post Code :

    NCA Ref : 200169

    City : Taizhou

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    GMP Certified

    EU
    AACR Annual meeting
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    AACR Annual meeting
    Not Confirmed

    Zhejiang Hisoar Pharmaceutical

    Type : GMP Certificates

    Number : DE_SH_01_GM...

    EudraGMDP Key : 31482

    Country : China

    Issue Date : 2014-10-07

    Post Code :

    NCA Ref : 00021501

    City : Zhejiang Province

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    GMP Certified

    EU
    AACR Annual meeting
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    AACR Annual meeting
    Not Confirmed

    Zhejiang Hisoar Pharmaceutical

    Type : GMP Certificates

    Number : UK API 2035...

    EudraGMDP Key : 11534

    Country : China

    Issue Date : 2011-07-08

    Post Code :

    NCA Ref : 3316519-ZHEJ...

    City : LINHAI CITY

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    GDUFA

    read-more
    read-more

    01

    GDUFA fees paid

    USA
    AACR Annual meeting
    Not Confirmed
    arrow

    GDUFA fees paid

    USA
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Paid in : 2024

    Zhejiang Hisoar Pharmaceutical

    API Manufacturer : API MANUFACTURE

    FDF Manufacturer :

    Facility Name : Zhejiang Hisoar Chuannan Pharm...

    Business Address : No. 23, Donghai 5th Ave., Zh...

    FEI Number : 3006545436

    Country : China

    Paid in : 2024

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    GDUFA fees paid

    USA
    AACR Annual meeting
    Not Confirmed
    arrow

    GDUFA fees paid

    USA
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Paid in : 2022

    Zhejiang Hisoar Pharmaceutical

    API Manufacturer : API MANUFACTURE

    FDF Manufacturer :

    Facility Name : Zhejiang Hisoar Pharmaceutical...

    Business Address : No. 100, Waisha Branch Rd., ...

    FEI Number : 3003735151

    Country : China

    Paid in : 2022

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact Zhejiang Hisoar Pharmaceutical and get a quotation

    Zhejiang Hisoar Pharmaceutical is a supplier offers 32 products (APIs, Excipients or Intermediates).

    Find a price of Clindamycin Hydrochloride bulk with DMF, CEP, JDMF offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Clindamycin Phosphate bulk with DMF, CEP, JDMF offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Amorolfine Hydrochloride bulk with CEP, JDMF offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Metoprolol Succinate bulk with DMF, CEP offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Quetiapine Hemifumarate bulk with CEP, JDMF offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Repaglinide bulk with CEP, JDMF offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Clindamycin Palmitate bulk with DMF offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Clindamycin Phosphate bulk with JDMF offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Flunixin Meglumine bulk with CEP offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Meropenem bulk with JDMF offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Voglibose bulk with JDMF offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Atorvastatin bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Biapenem bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Bifendate bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Caspofungin bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Clindamycin Palmitate bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Crisaborole bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Diquafosol Sodium bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Ertapenem Sodium bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Faropenem bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Florfenicol bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Gamithromycin bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Lifitegrast bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Moxidectin bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Phenylephrine Hydrochloride bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Rivaroxaban bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Rosuvastatin Calcium bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Sacubitril-Valsartan bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Sofalcone bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Tacrolimus bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Thiamphenicol bulk offered by Zhejiang Hisoar Pharmaceutical

    Find a price of Vortioxetine Hydrobromide bulk offered by Zhejiang Hisoar Pharmaceutical

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search